Brooklyn ImmunoTherapeutics (BTX) – Corporate News
-
Brooklyn ImmunoTherapeutics (BTX) Reports Phase 2 Study of IRX-2 Did Not Reach Endpoint
-
Brooklyn ImmunoTherapeutics (BTX) Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim CEO and President, Andrew Jackson Appointed CFO; Postpones 2022 Annual Meeting
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to BTX Stock Lookup